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were seen in follow-up visits 2 to 5 months after their
episode of SAVT, at which time none of the five had any
symptoms. None of the seven patients were seen at any
interval after 5 months. If the nonrespondents had good
outcomes (mild or no symptoms), this would not affect
our present interpretation of the data.
In conclusion, on the basis of this series of patients, we
believe that anticoagulation and a nonoperative approach
after initial thrombolysis is appropriate. Treatment for this
condition should be individualized, and patients who have
symptoms that impair them at work or with activities that
are important to them should then be offered surgical
decompression. However, many patients have few or no
symptoms and will function well without surgery.
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CORRECTION
There is an error in the abstract “Prevention of pulmonary embolism and deep vein thrombosis with low dose
aspirin: Pulmonary Embolism Prevention (PEP) trial (Pulmonary Embolism Prevention [PEP] Trial Collaborative
Group. Lancet 2000;355:1295-302) in the “Suggested Reading Abstracts” section of the February issue of the Journal
of Vascular Surgery. The last line of the abstract should read: “The authors conclude there is now good evidence for
considering aspirin routinely in a wide range of surgical and medical patients.” It currently reads “no good evidence.”
